Patents Assigned to Deutsches Krebsforschungszentrum Stiftung Des
Öffentlichen Rechts
-
Publication number: 20180066317Abstract: The present invention pertains to methods for classifying tumorous diseases based on their specific genomic DNA methylation profile. The invention provides a method that allows for a classification of a tumor sample obtained from a patient by analysing a multitude, preferably genome wide, collection of CpG positions by comparison to a classification rule derived from a set of methylation data acquired from pre-classified tumor species. The invention is in particular useful for classifying brain tumor samples since brain tumors are characterized by a large variety of distinct tumor species which have different prognostic values and require in the clinic a for each species developed treatment regime.Type: ApplicationFiled: September 15, 2016Publication date: March 8, 2018Applicants: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Ruprecht-Karls-Universität HeidelbergInventors: STEFAN PFISTER, ANDREAS VON DEIMLING, DAVID JONES, DAVID CAPPER, VOLKER HOVESTADT, MARTIN SILL, MELANIE BEWERUNGE-HUDLER, MATTHIAS SCHICK
-
Patent number: 9861669Abstract: Described is a parvovirus for preventing recurrence of a tumor, preferably a malignant brain tumor or pancreas tumor.Type: GrantFiled: May 19, 2010Date of Patent: January 9, 2018Assignees: Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Ruprecht-Karls-Universitaet HeidelbergInventors: Jean Rommelaere, Zahari Raykov, Svitlana Grekova, Irina Kiprijanova, Karsten Geletneky, Ute Koch, Marc Aprahamian
-
Patent number: 9850308Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.Type: GrantFiled: April 30, 2015Date of Patent: December 26, 2017Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS, UNIVERSITAETSKLINIKUM HEIDELBERGInventors: Ana Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez
-
Publication number: 20170254803Abstract: The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (MHC) class I or II. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule. The binding agents of the invention are coupled to proximity probes which upon antigen presentation elicit a detectable signal. The method of the invention allows detecting antigen presentation via MHC in-vitro and in a tissue sample in-situ. Thus the method of the present invention finds application as a new diagnostic tool, for example in the diagnosis of various diseases such as infectious diseases, immunological disorders, in particular autoimmune diseases, and proliferative disorders such as cancer.Type: ApplicationFiled: October 22, 2015Publication date: September 7, 2017Applicant: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Michael PLATTEN, Wolfgang WICK, Lukas BUNSE, Theresa BUNSE, Felix SAHM
-
Patent number: 9752985Abstract: For the combinatorial synthesis of molecule libraries, substances are embedded in a matrix consisting of a first solvent thereby forming transport units in a solid state of aggregation at a temperature of less than 90° C. and wherein after application to a support, the physical environment of the transport units is modified by the application of a physical process such as a laser printer whereby the substances in the transport units are linked to the support.Type: GrantFiled: June 13, 2001Date of Patent: September 5, 2017Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS, EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIEInventors: Annemarie Poustka, Frank Breitling, Karl-Heinz Gross, Stefan Dübel, Rainer Saffrich
-
Patent number: 9498132Abstract: A sensor means is employed to sense a distance to the surface of a subject to be examined, so that a range image may be acquired. Intensity information may be acquired alongside the distance information. The distance information and intensity information may be evaluated to track the pose of the sensor means relative to the surface of the subject to be examined, so that anatomical data related to said subject may be displayed as seen from the position and/or orientation of the sensor means or display means. By moving the sensor means or display means along the surface of the subject to be examined, such as a patient in a hospital environment, the user hence gets the impression of being able to look directly into the human body.Type: GrantFiled: May 10, 2013Date of Patent: November 22, 2016Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Lena Maier-Hein, Markus Fangerau, Hans-Peter Meinzer, Alexander Seitel
-
Publication number: 20160311861Abstract: The present invention relates to novel amino acid sequences of peptides derived from HPV16 that are able to bind to MHC complexes of class II, and elicit an immune response. The present invention further relates to pharmaceutical products, such as vaccines and T-cells, based on said epitopes.Type: ApplicationFiled: December 1, 2014Publication date: October 27, 2016Applicant: Deutsches Krebsforschungszentrum Stiftung des Öffentlichen RechtsInventors: Agnieszka GRABOWSKA, Angelika RIEMER
-
Patent number: 9446099Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-?, and the use of said composition for treatment of cancer, e.g., a brain tumor.Type: GrantFiled: May 19, 2010Date of Patent: September 20, 2016Assignees: Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Ruprecht-Karls-Universitaet HeidelbergInventors: Irina Kiprijanova, Manuel Fischer, Jean Rommelaere, Joerg Schlehofer, Karsten Geletneky
-
Publication number: 20160115236Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.Type: ApplicationFiled: April 30, 2015Publication date: April 28, 2016Applicants: Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts, Universitaetsklinikum HeidelbergInventors: Ana MARTIN-VILLALBA, Susanne KLEBER, Benedikt WIESTLER, Peter G. KRAMMER, Christel HEROLD-MENDE, Ignacio SANCHO-MARTINEZ
-
Patent number: 9309320Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.Type: GrantFiled: December 28, 2007Date of Patent: April 12, 2016Assignees: Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Universitaetsklinikum HeidelbergInventors: Ana Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez
-
Patent number: 9108941Abstract: The invention relates to compounds of the formula (I), where the symbols have the meaning given in the specification, for use in a method for treating cancer, to use of these compounds for the manufacture of a pharmaceutical composition for the treatment of cancer, and to methods of treatment for said diseases employing a compound of formula (I).Type: GrantFiled: December 22, 2009Date of Patent: August 18, 2015Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTSInventors: Alwin Kraemer, Blanka Leber, Mads Clausen, Thomas Larsen, Mads Roennest, Kasper Worm
-
Patent number: 8992923Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.Type: GrantFiled: February 22, 2013Date of Patent: March 31, 2015Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Oeffentlichen RechtsInventors: Hai-Kun Liu, Guenther Schuetz
-
Patent number: 8926970Abstract: The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.Type: GrantFiled: October 8, 2013Date of Patent: January 6, 2015Assignee: Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen RechtsInventors: Christof Niehrs, Olga Kazanskaya, Bisei Okawara
-
Publication number: 20140234261Abstract: Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.Type: ApplicationFiled: March 7, 2013Publication date: August 21, 2014Applicants: Ruprecht-Karls-Universitaet Heidelberg, Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen RechtsInventors: Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Ruprecht-Karls-Universitaet Heidelberg
-
Publication number: 20140120117Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: ApplicationFiled: October 3, 2013Publication date: May 1, 2014Applicants: MediGene AG, Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen RechtsInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Patent number: 8653464Abstract: The invention relates to an imaging method for simultaneously determining in vivo distributions of bioluminescent and/or fluorescent markers and radioactive markers at identical projection angles, the distribution of the bioluminescent and/or fluorescent markers being determined by separate detection of photons having a first average energy, which are emitted by the bioluminescent and/or fluorescent markers, by means of at least one first detector and the distribution of the radioactive markers being determined by simultaneous separate detection of photons having a second average energy, which are emitted by the radioactive markers, by means of at least one second detector. Furthermore, it also relates to an apparatus for carrying out the imaging method, containing at least one micro lens array optical tomographic imaging system as first detector, at least one single photon emission computer tomography (SPECT) detector as second detector.Type: GrantFiled: October 10, 2008Date of Patent: February 18, 2014Assignee: Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen RechtsInventor: Joerg Peter
-
Patent number: 8565378Abstract: The invention relates to a method and device for operating collimator (1) for limiting a beam of high-energy radiation (2) which, starting from an essentially point-shaped radiation source (3), is directed onto an object (4) to be treated and which is used especially for stereotactic, conformal radiation therapy of tumors, wherein the collimator (1) has an iris diaphragm (5) as a beam-limiting means.Type: GrantFiled: May 5, 2010Date of Patent: October 22, 2013Assignee: Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen RechtsInventor: Gernot Echner
-
Publication number: 20130189267Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.Type: ApplicationFiled: February 22, 2013Publication date: July 25, 2013Applicant: DKFZ Deutsches Krebsforschungszentrum, Stiftung Des Oeffentlichen RechtsInventor: DKFZ Deutsches Krebsforschungszentrum, Stiftung Des Oeffentlichen Rechts
-
Patent number: 8404657Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.Type: GrantFiled: November 18, 2008Date of Patent: March 26, 2013Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Oeffentlichen RechtsInventors: Hai-Kun Liu, Günther Schütz
-
Patent number: 8361440Abstract: The invention relates to an imaging method for simultaneously determining in vivo distributions of bioluminescent and/or fluorescent markers and radioactive markers at identical projection angles, the distribution of the bioluminescent and/or fluorescent markers being determined by separate detection of photons having a first average energy, which are emitted by the bioluminescent and/or fluorescent markers, by means of at least one first detector and the distribution of the radioactive markers being determined by simultaneous separate detection of photons having a second average energy, which are emitted by the radioactive markers, by means of at least one second detector.Type: GrantFiled: June 11, 2003Date of Patent: January 29, 2013Assignee: Deutsches Krebsforschungszentrum Stiftung des Öffentlichen RechtsInventor: Jörg Peter